Dr. Yan Valle

Prof. Yan Valle
Vitiligo Research Foundation (New York, USA)

Patient-reported outcomes in vitiligo: therapeutic, demographic, socio-economic and other previously unseen correlations.
AUTHOR: Prof. Yan Valle 

A 5-year long online survey revealed previously unreported correlations that could help clinicians better manage patient expectations and treatment outcomes. The Vitinomics survey was designed as a web-based questionnaire with 40 inputs. The questions included demographics, skin type, eye and natural hair color, age of respondent and age of onset, possible triggers, disease extent, localization, progression and activity, the efficacy of most common treatment modalities, medication side-effects, heredity and diseases among parents, and out-of-pocket expenses for treatments to date.
Patients seeking treatments are the majority of the vitiligo population; men are slightly more likely than women to seek treatments (83.3% vs 81.9%). However, positive results were “never seen” by 49% of survey respondents, while 22% of them are “not sure” if they had seen any results.
Analysis revealed that most patients will drop out because of perceived treatment in/efficiency in relation to expenses. Most of those patients who followed treatment protocol for under three months and/or spent under $500 have never seen any positive results. Those people who stick to one-year treatment protocol, would have seen positive results after spending close to $5,000.
We will discuss a broad range of barriers to effective treatment outcomes and links between therapies, socio-economic factors, and treatment outcomes in vitiligo. Dermatologists should actively manage patient’s expectations of treatment duration, likely outcomes and expected out-of-pocket expenses. A more aggressive therapeutic approach and evaluation at shorter intervals is desirable, in order to achieve a patient satisfaction and increase quality of life.


Centro Studi per la Ricerca Multidisciplinare Rigenerativa 2014 – present
Università degli Studi Guglielmo Marconi
Vitiligo Research Foundation (New York, USA) 2010 – present
Chief Executive Officer
Ethnic Television Network (Toronto, Canada) 2007-2010
VP, Business Development
Airborne Media (Toronto, Canada) 2000-2007
Director, Business Development
RuConsulting (Moscow, Russia) 1992-2000
Director, Business Development

Master of Business Administration 1992-1993
Academy For National Economy (Moscow, Russia)
Master of Science, Electroengineering
Russian Technology University, RTU MIREA (Moscow, Russia) 1987-1992

Associated Editor: Dermatologic Therapy, Wiley 2018 – present
Associated Editor: World Health Academy Publication House 2012 – present

1. Patient-reported outcomes: a five-year long study reveals previously unreported therapeutic, demographic, socio-economic and other correlations in vitiligo. Dermatol Ther. 2018 Sep;31(5):e12620. doi: 10.1111/dth.12620. Epub 2018 Sep 25.
2. Controversial issues in vitiligo patients: a review of old and recent treatments. Dermatol Ther. 2018 Sep 17:e12745. doi: 10.1111/dth.12745.
3. Functional nutrition as integrated approach in vitiligo management. Dermatol Ther. 2018 Aug 28:e12625. doi: 10.1111/dth.12625.
4. An Innovative Therapeutic Protocol for Vitiligo: Experience with the Use of Fraxel Herbium Laser, Topical Latanoprost and Successive Irradiation with UVA – 1 Laser. Open Access Maced J Med Sci. 2018 Jan 21;6(1):49-51. doi: 10.3889/oamjms.2018.059. eCollection 2018 Jan 25.
5. Micro – Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo. Vol. 6 No. 1 (2018): Jan 25 (OAMJMS) Global Dermatology-2
6. A No-Nonsense Guide To Vitiligo. ASIN Paperback: 1973371049. November 2017
7. Vitiligo: A Step-By-Step Guide to Diagnosis, Treatment And Prophylaxis. VR Foundation. ASIN: B077Q37PFZ. November 2017
8. Artificial Hair: By the Dawn to Automatic Biofibre® Hair Implant. Open Access Maced J Med Sci. 2017 Dec 30;6(1):156-162. doi: 10.3889/oamjms.2018.001. eCollection 2018 Jan 25.
9. Enhanced genome-wide association studies of autoimmune vitiligo identify 23 novel loci and highlight key pathobiological pathways and causal regulatory variation. Nat Genet. 2016 Nov;48(11):1418-1424. doi: 10.1038/ng.3680. Epub 2016 Oct 10.
10. Methods of Vitiligo Treatment. Collective Monography. ISBN: 978-601-80599-3-3. 2016
11. VITILIGO. Perspektive I Smjernice. ISBN: 978-953-7959-26-5 HDVD HLZ-a. April 2015.
12. Vitiligo: Challenges and Opportunities for social entrepreneurs and community. Pigmentary Disorders. 1/5. November 2014.
13. Letter to Editor on the World Vitiligo Day Campaign. Pigmentary Disorders: 1/1. June 2014.
14. Natural Antioxidants in General Medicine and in Dermatology. World Health Academy Publishing House. ASIN: B00BKWE3ZU. February 2013
15. Vitiligo : What’s New, What’s True. World Health Academy Publishing House. ASIN: B00DH2RJZ2. June 2013.
16. Multidisciplinary approach to R&D in vitiligo, a neglected skin disease. Dermatol Ther. 2012 Nov-Dec;25 Suppl 1:S1-9. doi: 10.1111/dth.12009.
17. Treatments of vitiligo: what’s new at the horizon. Dermatologic Ther. 2012 Sept-Oct; 25: S32–S40, 2012
18. Vitiligo road map. Dermatol Ther. 2012 Nov-Dec;25 Suppl 1:S44-56. doi: 10.1111/dth.12006.
19. Cloud Medical Research Management: a Bio-IT tool for correlative studies in dermatology. Treat Strategies (Dermatol). 1(1): 82-86, 2011

Contactează operatorul PDI 2019

11 + 1 =

Operatorul PDI 2019

Adresa: Str. A. Panu nr. 13, Iasi
Tel.: 0332.40.88.00-05
E-mail: inscrieri@primaderma.ro/2019
Website: www.eventernet.ro